CONNECTA Therapeutics Secures $2.5M Grant to Pioneer First-in-Class Fragile X Syndrome Therapy

CONNECTA Therapeutics S.L. is thrilled to announce a successful funding round, raising €2,500,000 as it advances its mission to innovate treatments for CNS unmet medical needs. This investment marks a significant milestone in the company’s journey to transform the landscape of neurodevelopmental therapeutics. Founded with a commitment to addressing disorders lacking effective interventions, CONNECTA Therapeutics is now poised to further develop its exciting new “first-in-class” molecule, specifically designed to treat Fragile X Syndrome (FXS). FXS, known as the most common hereditary cause of intellectual disability, remains an area with an urgent clinical need given the absence of current therapeutic options. The breakthrough molecule, which emerged after an extensive evaluation of more than 30 molecular and cellular targets, has demonstrated remarkable potential. In both in vitro tests and in vivo animal models, the molecule proved to be a superior neuroplasticity modulator with promising effects that could extend to other neurodevelopmental disorders such as Rett syndrome, Down syndrome, and autism spectrum disorders. The funding will be instrumental in advancing clinical development programs, supporting expanded research, and setting the groundwork for future multi-center clinical trials aimed at evaluating the therapeutic potential of this novel compound. This injection of capital not only highlights the confidence investors have in CONNECTA Therapeutics’ innovative approach but also solidifies the company's role as a pioneer in addressing unmet clinical needs in the central nervous system arena. With a clear vision and robust scientific backing, CONNECTA Therapeutics is dedicated to bringing new hope to patients and families affected by fragile X syndrome and related neurodevelopmental conditions, forging a new era in personalized medicine and targeted therapy.